Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Telix Pharmaceuticals Limited
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
December 19, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
November 18, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix ADSs Commence Trading on Nasdaq
November 13, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
November 13, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
November 03, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
October 30, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
October 23, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
October 22, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Files Form 20-F Registration Statement for Nasdaq ADS
October 17, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
October 17, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
October 03, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
September 22, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
September 17, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
CAH
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
September 10, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
September 03, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
August 27, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Announces Reorganisation to Deliver on Strategic Priorities
August 26, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
August 22, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
July 29, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
July 23, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Q2 2024 Revenue and Business Highlights, Guidance Upgrade
July 17, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
July 10, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Announces Launch of Proposed Initial Public Offering in the United States
June 05, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
June 02, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
May 30, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Submits NDA for New Prostate Cancer Imaging Agent
May 28, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
May 20, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
May 17, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Q1 2024 Revenue and Business Update
April 17, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
April 15, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Tickers
ASX:TLX
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.